Literature DB >> 27712695

Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report.

Sorrel E Wolowacz1, Andrew Briggs2, Vasily Belozeroff3, Philip Clarke4, Lynda Doward1, Ron Goeree5, Andrew Lloyd6, Richard Norman7.   

Abstract

Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data. However, trials designed primarily to evaluate efficacy and safety often present challenges to the optimal collection of HSU estimates for economic models. Careful planning is needed to determine which of the HSU estimates may be measured in planned trials; to establish the optimal methodology; and to plan any additional studies needed. This report aimed to provide a framework for researchers to plan the collection of health-utility data in clinical studies to provide high-quality HSU estimates for economic modeling. Recommendations are made for early planning of health-utility data collection within a research and development program; design of health-utility data collection during protocol development for a planned clinical trial; design of prospective and cross-sectional observational studies and alternative study types; and statistical analyses and reporting.
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  economic model; health-utility; recommendations

Mesh:

Year:  2016        PMID: 27712695     DOI: 10.1016/j.jval.2016.06.001

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  37 in total

1.  Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.

Authors:  Tomas Mlcoch; Jan Tuzil; Liliana Sedova; Jiri Stolfa; Monika Urbanova; David Suchy; Andrea Smrzova; Jitka Jircikova; Tereza Hrnciarova; Karel Pavelka; Tomas Dolezal
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 2.  International Regulations and Recommendations for Utility Data for Health Technology Assessment.

Authors:  Donna Rowen; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 3.  Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies.

Authors:  Roberta Ara; John Brazier; Tracey Young
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care.

Authors:  Roberta Ara; Tessa Peasgood; Clara Mukuria; Helene Chevrou-Severac; Donna Rowen; Ismail Azzabi-Zouraq; Suzy Paisley; Tracey Young; Ben van Hout; John Brazier
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 5.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 6.  The Identification, Review and Synthesis of Health State Utility Values from the Literature.

Authors:  Roberta Ara; John Brazier; Tessa Peasgood; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

7.  Community perspectives on difference of sex development (DSD) diagnoses: A crowdsourced survey.

Authors:  M Hassan Alkazemi; Ashley W Johnston; Diane Meglin; Deanna Adkins; Jonathan C Routh
Journal:  J Pediatr Urol       Date:  2020-04-27       Impact factor: 1.830

8.  Establishing benchmark EQ-5D-3L population health state utilities and identifying their correlates in Gansu Province, China.

Authors:  Lei Si; Lei Shi; Mingsheng Chen; Andrew J Palmer
Journal:  Qual Life Res       Date:  2017-06-07       Impact factor: 4.147

9.  Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.

Authors:  Daisuke Goto; Ya-Chen Tina Shih; Pascal Lecomte; Melvin Olson; Chukwukadibia Udeze; Yujin Park; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

Review 10.  The Use of Health State Utility Values in Decision Models.

Authors:  Roberta Ara; John Brazier; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.